imiquimod has been researched along with Peritonitis in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Azam, T; Beckman, K; de Graaf, DM; Dinarello, CA; Fischer, S; Fujita, M; Højen, JF; Kristensen, MLV; Lunding, LP; McKee, AS; Swartzwelter, BJ; Tolstrup, M; Wade, MT; Wegmann, M | 1 |
Cheung, PH; Foreman, O; Hain, HS; Kaur, P; Kavirayani, A; Saha, S; Tung, D | 1 |
2 other study(ies) available for imiquimod and Peritonitis
Article | Year |
---|---|
IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease.
Topics: A549 Cells; Animals; Antibodies, Blocking; Antibodies, Monoclonal; Cell Line, Tumor; Disease Models, Animal; HEK293 Cells; Humans; Imiquimod; Inflammation; Interleukin-1; Interleukin-1 Receptor Accessory Protein; Interleukin-1beta; Interleukin-33; Male; Mice; Mice, Inbred C57BL; Ovalbumin; Peritonitis; Pneumonia; Psoriasis; Signal Transduction; Uric Acid | 2019 |
Anti-inflammatory and immunomodulatory effects of bortezomib in various in vivo models.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Dinitrofluorobenzene; Disease Models, Animal; Drug Compounding; Drug Evaluation, Preclinical; Drug Stability; Female; Hypersensitivity, Delayed; Imiquimod; Immunologic Factors; Irritants; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Peritonitis; Psoriasis; Pyrazines; Random Allocation; Temperature; Thioglycolates | 2011 |